Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Rebranding Signals Strategic Shift Beyond Biopharmaceuticals, Highlights Commitment to Technology, Artificial Intelligence and Shareholder Value

WEXFORD, Pa., Jan. 30, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce its rebranding to COEPTIS, marking a transformative shift in its business strategy. This pivotal change reflects our commitment to expanding beyond biopharmaceuticals and embracing diverse growth opportunities in technology-driven sectors.
With the establishment of our new Technology Division, COEPTIS aims to enhance operational capabilities and maximize shareholder value. Central to this initiative was the recent acquisition of the NexGenAI Affiliates Network platform, a groundbreaking AI-powered marketing solution. This acquisition aligns seamlessly with COEPTIS's mission to innovate in highly regulated industries, revolutionizing marketing strategies and operational efficiencies.

Read more at prnewswire.com